Patent classifications
A61K38/193
METHODS AND COMPOSITIONS FOR TREATING ACUTE LUNG INJURY AND ACUTE RESPIRATORY DISTRESS SYNDROME
Compositions and methods related to the treatment of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) including viral pneumonia through the pharmaceutical manipulation of calcium signaling are disclosed. Such compositions and methods may be used to reduce pro-inflammatory cytokine releases that may lead to ALI and/or ARDS.
METHODS AND COMPOSITIONS FOR TREATING ACUTE LUNG INJURY AND ACUTE RESPIRATORY DISTRESS SYNDROME
Compositions and methods related to the treatment of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) including viral pneumonia through the pharmaceutical manipulation of calcium signaling are disclosed. Such compositions and methods may be used to reduce pro-inflammatory cytokine releases that may lead to ALI and/or ARDS.
VIRAL VECTORS FOR CANCER THERAPY
The present disclosure provides recombinant nucleic acids comprising one or more polynucleotides encoding an immunomodulatory polypeptide (e.g., a pro-inflammatory cytokine such as a human IL-2 or IL-12 polypeptide); viruses comprising the recombinant nucleic acids; compositions and formulations comprising the recombinant nucleic acids and/or viruses; methods of their use (e.g., for the treatment of cancer, such as lung cancer); and articles of manufacture or kits thereof.
GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR-BASED INFECTION TREATMENTS
The present disclosure relates to the treatment of infection with coronaviruses with granulocyte-macrophage colony-stimulating factor.
GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR-BASED INFECTION TREATMENTS
The present disclosure relates to the treatment of infection with coronaviruses with granulocyte-macrophage colony-stimulating factor.
Therapeutic use of electroacupuncture-induced mesenchymal stem cells
Stimulation using EA of LI-4, LI-11, GV-14 and GV-20 in humans, horses, and rodents results in mobilization of MSCs into systemic circulation. Methods are provided for increasing mesenchymal stem cells in the circulating blood of a mammal by contacting acupuncture points LI-4, LI-11, GV-14, and GV-20 of the mammal with a therapeutically effective amount of EA stimulation to mobilize MSCs into the circulating blood of the mammal. Methods for treating damaged tissue, specifically damaged tendons are also provided. Isolated mesenchymal stem cells made according to these methods, methods of isolated them, and stem cell banks that store them are also provided.
POLYMER DERIVATIVES HAVING PARTICULAR ATOM ARRANGEMENTS
Polymeric reagents are provided comprising a moiety of atoms arranged in a specific order, wherein the moiety is positioned between a water-soluble polymer and a reactive group. The polymeric reagents are useful for, among other things, forming polymer-active agent conjugates. Related methods, compositions, preparations, and so forth are also provided.
INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR MODULATING HEMATOPOIETIC STEM CELLS AND HEMATOPOIESIS
A method of modulating hematopoietic stem cells and hematopoiesis includes administering to a subject in need thereof a 15-PGDH inhibitor.
INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR MODULATING HEMATOPOIETIC STEM CELLS AND HEMATOPOIESIS
A method of modulating hematopoietic stem cells and hematopoiesis includes administering to a subject in need thereof a 15-PGDH inhibitor.
3-substituted piperidine compounds for Cbl-b inhibition, and use thereof
Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo. Also disclosed are pharmaceutical compositions comprising a Cbl-b inhibitor and a cancer vaccine, as well as methods for treating cancer using a Cbl-b inhibitor and a cancer vaccine; and pharmaceutical compositions comprising a Cbl-b inhibitor and an oncolytic virus, as well as methods for treating cancer using a Cbl-b inhibitor and an oncolytic virus.